Savaria(DE:S97)
€18.500.00 (0.00%)
DE:S97
Savaria earnings date
€18.50
At close:0.00 (0.00%)
Savaria (S97) Q3 2026 Earnings Report
0 Followers
DE:S97 Q3 2026 EPS Results
- Actual EPS
- EUR 0.20
- Consensus EPS
- EUR 0.22
- Beat/Miss
- Missed by -EUR 0.02
- One Year Ago EPS
- EUR 0.20
DE:S97 Q3 2026 Revenue Results
- Actual Revenue
- EUR 154.62M
- Expected Revenue
- EUR 153.15M
- Beat/Miss
- Beat by +EUR 1.47M
- YoY Revenue Growth
- +9.01%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
DE:S97 Upcoming Earnings
Savaria's next earnings date is estimated for March 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by record adjusted EBITDA, 9% revenue growth with 6.8% organic growth, higher operating income and net earnings, strong Accessibility performance, product momentum, acquisition progress, improved liquidity, and lower debt. The main challenges were the decline in Patient Care margins, material and logistics inflation, higher foreign exchange losses, lower operating cash flow, and increased investment outflows. Management remained confident in Q4 margin improvement and its long-term growth strategy.
Company Guidance
Savaria said it has the ambition to grow the business at 12% per year in the next 5 years and maintain EBITDA margins at 20% plus, leading to $1.6 billion of sales with over $220 million of EBITDA; it also targets consolidated organic growth of 7% to 8% per year, around $200 million of acquisitions in the next 5 years, and 4% to 5% of acquisition per year. CapEx is expected to end the year at around the high 3%, 3.8%, I think, range, continue for Q4, and return next year to more in the 2.5% range of revenue; Patient Care margins are expected to come back better in the coming quarter, with improvement targeted in Q4 of this year, while inventory is expected to decrease substantially in the fourth quarter ahead of year-end.
- Record Adjusted EBITDA and Stable MarginAdjusted EBITDA reached a record $52.1 million in Q3, with an EBITDA margin of 21.2%, unchanged from $47.6 million and 21.2% in Q3 2025.
- Strong Revenue GrowthQ3 revenue increased 9% to $245 million, including 6.8% organic growth, a 1.4% contribution from the Baxter and Vipal acquisitions, and a 0.8% positive foreign exchange impact. Year-to-date revenue increased 8.1% to $726.4 million.
- Operating Income and Net Earnings GrowthOperating income increased 28.6% to $35.6 million, with the margin rising to 14.5% from 12.3% last year. Year-to-date operating income increased 38% to $104.4 million. Net earnings increased 18.4% to $23.1 million, or $0.32 per diluted share, from $19.5 million, or $0.27 per diluted share.
- Accessibility Segment PerformanceAccessibility revenue increased 9.1% to $196.5 million, including 6.6% organic growth, with sales increasing in all regions and another strong quarter in Europe. Accessibility adjusted EBITDA margin reached 24.2%, up from 23.5% last year, a 70-basis-point improvement.
- Patient Care Revenue GrowthPatient Care revenue increased 8.6% to $48.6 million, including 7.5% organic growth, driven by higher project sales in North America and continued growth from the U.K. location.
- Gross Margin ResilienceConsolidated gross margin increased 10 basis points to 39.3% from 39.2% in Q3 2025, while gross profit increased $8.2 million year over year. Management said this demonstrated the ability to continue increasing gross margins under the current tariff environment.
- Home Elevator Growth and Product ExpansionHome elevator and stairlift products remained the main drivers of Accessibility growth. Management cited strong home elevator sales, efforts to gain market share, dealer training, national-builder engagement, new options such as cabs and touchscreen COPs, and the Luma product family.
- Positive Reception for New ProductsThe larger Luma L received an enthusiastic dealer response at the NAEC exhibition and strong interest at the Grand Designs show in the U.K. It became available in North America in October and is scheduled to become available in Europe in January 2027. The new Precision Cab was also very well received at NAEC, while the Outdoor 4000 rail was described as a big commercial success.
- Product Pipeline and R&D InvestmentSavaria continues to build its product roadmap with 60 people in R&D across its business segments. The company is planning a new Artira model, currently on track and undergoing field trials in Europe, and is expanding the accessories and lineup for ceiling lifts and beds.
- Manufacturing and Vertical Integration InvestmentsSavaria designs and manufactures its own electronic PCB in the U.K., has contributions from its China and Mexico factories, and has invested in machinery in its local factories to improve productivity and custom-product lead times. Greenville continues to manufacture approximately 50% of home elevators, with its building expansion on plan for completion by the end of Q4.
- Strategic Acquisition ProgressSavaria acquired Baxter Elevator in Texas and Vipal in Italy during the year. Vipal adds a small home-lift lineup and a low-rise commercial elevator, supporting European growth, and the company plans to begin selling Vipal products to European dealers in the next few months.
- Improved Liquidity and Lower DebtAvailable funds increased to $337.7 million at September 30 from $311.7 million at year-end, while net debt decreased to $173.2 million from $191.5 million. The net debt ratio was 0.85 at the end of Q3, supporting continued investment and capital allocation.
- Progress Across North America and EuropeNorth American growth was fueled mostly by home elevator sales, direct stores continued to grow and become more professionalized, and the Matot dumbwaiter and material-lift brand continued to grow. In Europe, organic growth was supported by B2B dealer activity, the U.K. direct store, cross-selling of platform lifts in the U.K. and the Netherlands, and commercial actions in other markets.
- Patient Care Innovation and Order IntakePatient Care growth was led mostly by ceiling-lift sales and installation, with the M-Series contributing to product innovation and sales efforts. Management reported strong ceiling-lift and bed order intake in Q3 and said the quarter ended with a strong order book despite lower bed sales.
- Operational Cost and Quality InitiativesSavaria commissioned a new Greenville paint line to produce Precision home elevator cabs in-house, commissioned a new metal fabrication shop with laser cutters and bending capabilities in Huizhou, commonized European stairlift drawing platforms, redesigned the QD1000 bed frame to simplify manufacturing and improve quality, and set up a U.S. assembly line for clinical M-Series lifts.
- Additional Efficiency ImprovementsThe company improved the U.K. direct-business call-center service level while reducing reliance on external third-party support. Management also said procurement initiatives, supply-chain improvements, and operational initiatives remain in progress across its factories.
- Recurring Revenue and Savaria LinkService and maintenance represented approximately 10% to 15% of top-line revenue. Management said Savaria Link is in its early stages and is intended to help dealers troubleshoot products and improve installation and service efficiency.
- Long-Term Growth AmbitionsManagement reiterated its ambition to grow the business at 12% per year over the next five years while maintaining EBITDA margins at 20% plus, ultimately reaching $1.6 billion of sales and over $220 million of EBITDA. The company also cited an ambition of 7% to 8% annual organic growth and approximately $200 million of acquisitions over five years.
- Cost Savings MomentumManagement said a similar number of cost initiatives continue to be implemented each quarter and that at least one-third of the impacts or cost reductions come from these initiatives.
- Healthy Backlog and Future DemandManagement described the backlog as stable and healthy, citing stable production factories, strong lead times, and dealer ordering practices. The company also said the aging population and consumer preference to remain at home support its market opportunity.
DE:S97 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 10, 2027 | 2026 (Q4) | 0.23- | 0.23 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 0.220.20 | 0.2 | 0.00% (+0.00) | |
| Aug 05, 2026 | 2026 (Q2) | 0.210.22 | 0.18 | 20.69% (+0.04) | |
| May 06, 2026 | 2026 (Q1) | 0.200.20 | 0.15 | 34.78% (+0.05) | |
| Mar 04, 2026 | 2025 (Q4) | 0.200.23 | 0.13 | 85.00% (+0.11) | |
| Nov 05, 2025 | 2025 (Q3) | 0.190.20 | 0.11 | 77.78% (+0.09) | |
| Aug 06, 2025 | 2025 (Q2) | 0.150.18 | 0.09 | 93.33% (+0.09) | |
| May 07, 2025 | 2025 (Q1) | 0.100.15 | 0.1 | 43.75% (+0.04) | |
| Mar 05, 2025 | 2024 (Q4) | 0.130.13 | 0.1 | 25.00% (+0.03) | |
| Nov 06, 2024 | 2024 (Q3) | 0.130.11 | 0.11 | 0.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
